Miscellaneous antineoplastics

Tecartus genetically modified autologous T cells for infusion Images

Generic Name: brexucabtagene autoleucel

This medication has been identified as Tecartus genetically modified autologous T cells for infusion. It is supplied by Kite Pharma, Inc.

Tecartus is used in the treatment of Mantle Cell Lymphoma; Acute Lymphoblastic Leukemia and belongs to the drug class miscellaneous antineoplastics. Tecartus genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).

Images

Tecartus (Brexucabtagene autoleucel [ brex-ue-kab-ta-jeen-ah-toe-loo-sel ])-medicine-genetically modified autologous T cells for infusion
Tecartus (Brexucabtagene autoleucel [ brex-ue-kab-ta-jeen-ah-toe-loo-sel ])-medicine-genetically modified autologous T cells for infusion

Tecartus
Generic Name: brexucabtagene autoleucel [ brex-ue-kab-ta-jeen-ah-toe-loo-sel ]
Imprint: medicine
Strength: genetically modified autologous T cells for infusion
Color: N/A
Size: N/A
Shape: N/A
Availability: Prescription only
Drug Class: Miscellaneous antineoplastics
Pregnancy Category: N/A
CSA Schedule: Not a controlled drug
Labeler / Supplier: N/A
National Drug Code (NDC): 71287-0219
Inactive Ingredients:
Latest News
Related Drugs